Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTNASDAQ:FRTXNASDAQ:GTBPOTCMKTS:NSPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTConduit Pharmaceuticals$2.30-0.4%$5.24$2.21▼$2,197.50$1.84M2.02160,330 shs394,607 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGTBPGT Biopharma$3.32+3.4%$2.57$1.72▼$4.10$8.30M1.37245,927 shs105,900 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTConduit Pharmaceuticals+0.43%+0.43%-33.62%-81.25%-99.90%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+0.32%GTBPGT Biopharma+5.25%+13.83%+11.07%+36.02%+9.93%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTConduit PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma1.5779 of 5 stars3.82.00.00.00.60.00.6NSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00231.33% UpsideNSPXInspyr Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTConduit PharmaceuticalsN/AN/AN/AN/A($73.54) per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/ANSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTConduit Pharmaceuticals-$17.80M-$534.48N/A∞N/AN/AN/A-435.57%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)NSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/ALatest NSPX, GTBP, CDT, and FRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$304.95N/A-$20.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTConduit PharmaceuticalsN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTConduit PharmaceuticalsN/A1.311.31FRTXFresh Tracks TherapeuticsN/AN/AN/AGTBPGT BiopharmaN/A0.730.73NSPXInspyr TherapeuticsN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTConduit Pharmaceuticals3.29%FRTXFresh Tracks Therapeutics25.04%GTBPGT Biopharma8.15%NSPXInspyr Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipCDTConduit Pharmaceuticals30.93%FRTXFresh Tracks Therapeutics0.23%GTBPGT Biopharma3.40%NSPXInspyr Therapeutics0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTConduit Pharmaceuticals3800,000551,000Not OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGTBPGT Biopharma82.59 million2.50 millionNo DataNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableNSPX, GTBP, CDT, and FRTX HeadlinesRecent News About These CompaniesInspyr Supports Breast Cancer Survivors with 'More Than Just a Pink Ribbon' EventOctober 1, 2024 | msn.comEWTX Edgewise Therapeutics, Inc.April 4, 2024 | seekingalpha.comFAST joins with University of Pennsylvania to develop investigational AAV gene therapy for Angelman syndromeOctober 18, 2023 | news-medical.netMemo Therapeutics gets US FDA fast track designation for AntiBKV as treatment of BKV infection in renal transplant patientsMay 5, 2023 | pharmabiz.comDecibel Therapeutics gets European orphan drug designation for lead gene therapy candidate DB-OTOApril 3, 2023 | pharmabiz.comBrainStorm Cell Therapeutics announces US FDA committee to review BLA for NurOwn to treat amyotrophic lateral sclerosisMarch 29, 2023 | pharmabiz.comKuria Therapeutics completes US FDA pre-IND consultation for topical Nrf2 activator for corneal endothelial diseaseMarch 22, 2023 | pharmabiz.comCombined Therapeutics’ mRNA vaccine platform receives US patentMarch 16, 2023 | pharmabiz.comTG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, PredictionsMarch 4, 2023 | benzinga.comInspyr Therapeutics Announces New Holding Company Structure and Reverse Stock SplitOctober 12, 2021 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPX, GTBP, CDT, and FRTX Company DescriptionsConduit Pharmaceuticals NASDAQ:CDT$2.30 -0.01 (-0.43%) Closing price 04:00 PM EasternExtended Trading$2.38 +0.08 (+3.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.GT Biopharma NASDAQ:GTBP$3.32 +0.11 (+3.43%) Closing price 04:00 PM EasternExtended Trading$3.33 +0.01 (+0.33%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Inspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
